Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Hydrochlorothiazide ups risk of nonmelanoma skin cancer

09 Dec 2017

Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.

Researchers compared the patterns of HCTZ use between 80,162 NMSC patients and 1,603,345 age- and sex-matched controls. Those with SCC of the lip were excluded.

Conditional logistic regression analysis was used to calculate for the risk of basal cell carcinoma (BCC) or SCC with the frequency of HTCZ use. Adjustments were performed for potential confounder such as other medications and comorbidities.

The rate of high HCTZ usage in BCC patients was higher than in matched controls (2.7 vs 2.1 percent; odds ratio [OR], 1.29; 95 percent CI, 1.23 to 1.35). Similarly, significantly more SCC patients were high HCTZ users than matched controls (10.0 vs 2.8 percent; OR, 3.98; 3.68 to 4.31).

HCTZ use also showed a dose-response relationship with BCC and SCC, with those at the highest categories of exposure having the highest risks (OR for BCC, 1.54; 1.38 to 1.71; p<0.001 for trend; OR for SCC, 7.38; 6.32 to 8.60; p<0.001 for trend).

Similar trends were observed when the participants were grouped according to sex, age and tumour localization. Notably, none of the other diuretics and hypertensives showed significant relationships with the risk of SCC and BCC.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.